Get access
  • News
Powerful Medical
•
8. October 2020

Video: Panel discussion on healthcare digitalization at Forbes Technology 2020

  • News

Martin Herman, our co-founder and CEO at Powerful Medical and Martin Smatana (Chief Business Officer of Medannot) have participated in the Forbes Technology 2020 panel discussion on Healthcare Digitalization, where they discussed data, AI, and the products we are bringing to market. They explain how Powerful Medical aids doctors in the diagnosis and treatment of cardiovascular diseases using an AI-powered clinical assistant and how its subsidiary Medannot automates diagnostics and annotation in 3D radiology imaging.

Powerful Medical

Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.
About PMcardio:

PMcardio is the market leader in AI-powered diagnostics, addressing the world’s leading cause of death – cardiovascular diseases. The innovative clinical assistant empowers healthcare professionals to detect up to 40 cardiovascular diseases. In the form of a smartphone application, the certified Class IIb medical device interprets any 12-lead ECG image in under 5 seconds to provide accurate diagnoses and individualized treatment recommendations tailored to each patient.

About Powerful Medical:

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Don't miss these

More articles
Left Ventricular Systolic Dysfunction (LVSD) (2)
  • AI, Education, Research

Left Ventricular Systolic Dysfunction: The Basics and AI Advancements in Detection

In this comprehensive article, we delve into the intricacies of Left Ventricular Systolic Dysfunction (LVSD), thoroughly analyzing its symptoms, causes, and severity. We explore the latest advancements in diagnostic tools and real-world case studies.
  • AI, Case Studies, Heartfelt Impact, OMI

Dr. Schmelzer’s Turning Point: How a Severe Chest Pain Case Inspired PMcardio Adoption

The case of a 76-year-old patient with severe chest pain prompted Dr. Schmelzer to delve into the nuances of Occlusive Myocardial Infarction (OMI) versus the conventional STEMI/NSTEMI classification. His research led him to discover the PMcardio OMI AI model.
More articles

Join 25,000 healthcare professionals who are already taking advantage of AI

Register now

Ready to get started?

Get access

Powerful Medical is redefining the landscape of medical diagnostics with its AI-driven solutions. The company’s certified PMcardio platform revolutionizes the way cardiovascular diseases are detected, offering rapid and accurate diagnostics that pave the way for timely and effective treatment.

Products

Company

Resources

Legal

Envelope Linkedin-in Instagram Facebook-f

© Powerful Medical 2024

Privacy

&

Cookies

Legal

PMcardio is CE-marked as class IIb medical device under EU MDR and only certified for marketing in the European Union and the United Kingdom. PMcardio technology has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA. Not all modules of the PMcardio platform may be available in your region.

Prior to use, reference the Instructions for Use, for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

PMcardio is CE-marked as class IIb medical device under EU MDR and only certified for marketing in the European Union and the United Kingdom. PMcardio technology has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA. Not all modules of the PMcardio platform may be available in your region. Prior to use, reference the Instructions for Use, for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Sign up